ILMN Stock Overview
Offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
Illumina, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$126.18 |
| 52 Week High | US$148.98 |
| 52 Week Low | US$86.44 |
| Beta | 1.13 |
| 11 Month Change | -4.93% |
| 3 Month Change | 6.68% |
| 1 Year Change | 40.09% |
| 33 Year Change | -61.02% |
| 5 Year Change | -56.73% |
| Change since IPO | -19.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| ILMN | AT Life Sciences | AT Market | |
|---|---|---|---|
| 7D | -9.6% | -6.0% | 1.1% |
| 1Y | 40.1% | 1.4% | 1.2% |
Return vs Industry: ILMN exceeded the Austrian Life Sciences industry which returned 1.6% over the past year.
Return vs Market: ILMN exceeded the Austrian Market which returned 1.1% over the past year.
Price Volatility
| ILMN volatility | |
|---|---|
| ILMN Average Weekly Movement | 4.9% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in AT Market | 6.5% |
| 10% least volatile stocks in AT Market | 1.8% |
Stable Share Price: ILMN's share price has been volatile over the past 3 months compared to the Austrian market.
Volatility Over Time: ILMN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10,615 | Jacob Thaysen | www.illumina.com |
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Illumina, Inc. Fundamentals Summary
| ILMN fundamental statistics | |
|---|---|
| Market cap | €20.31b |
| Earnings (TTM) | -€1.50b |
| Revenue (TTM) | €4.17b |
4.8x
P/S Ratio-13.2x
P/E RatioIs ILMN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ILMN income statement (TTM) | |
|---|---|
| Revenue | US$4.39b |
| Cost of Revenue | US$1.42b |
| Gross Profit | US$2.97b |
| Other Expenses | US$4.55b |
| Earnings | -US$1.58b |
Last Reported Earnings
Sep 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.99 |
| Gross Margin | 67.61% |
| Net Profit Margin | -36.10% |
| Debt/Equity Ratio | 93.6% |
How did ILMN perform over the long term?
See historical performance and comparison